Is Ipamorelin FDA-Approved? Regulatory Status

The short version

The question is ipamorelin fda approved has a one-word answer: no. Ipamorelin has never been approved as a drug by the FDA — or by any other regulatory authority, anywhere — for any indication. That is not because it is new and still under review. It is because its clinical program effectively ended when its only Phase 2 trial, testing it for sluggish bowels after surgery, missed its goal ^[3].

Three facts fill out the picture. It was investigated and dropped, not merely never studied ^[3]. In 2024, the FDA tightened compounding-pharmacy access to it ^[11]. And it is banned in sport at all times, with the labs able to detect it in urine ^[7]. "Meds" in this site's name names a regulatory question this page answers honestly — it does not describe an approved medicine or a pharmacy.

Never approved — and why that's a verdict, not a gap

It is worth being precise about what "not FDA-approved" means here. For many research peptides, lack of approval simply reflects that no one ran the trials. Ipamorelin is different: the trials were run, at least to Phase 2, and the key one failed ^[3]. The only published Phase 2 randomized controlled trial (NCT00672074) gave 114 bowel-resection patients 0.03 mg/kg intravenously twice daily for up to 7 days and missed its primary endpoint — time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo, not statistically significant (p=0.15) ^[3].

No Phase 3 trial followed, and no approved indication exists ^[3]. The originator, Novo Nordisk, had characterized the compound in the 1990s ^[1] and mapped its human pharmacokinetics in 1999 ^[2], but the efficacy program did not deliver. The absence of approval is the outcome of a failed development effort, not an unfinished one.

The 2024 compounding decision

Regulatory attention to ipamorelin did not end with the failed trial. In 2024, the FDA removed ipamorelin acetate from Category 2 of the interim Section 503A bulk drug substances list — the framework governing which substances compounding pharmacies may use — following withdrawal of the nomination in September 2024 ^[11]. The agency reviewed both ipamorelin acetate and the free base at the October 29, 2024 Pharmacy Compounding Advisory Committee (PCAC) meeting ^[11].

The practical effect was to restrict compounding-pharmacy access to ipamorelin. It is not an approved bulk substance for compounding, and it remains marketed only as a research chemical. This is the most recent regulatory development and the one most relevant to how the compound circulates.

Banned in sport, detectable in urine

Separately from the FDA question, ipamorelin carries a clear anti-doping status: it is prohibited in sport at all times under the World Anti-Doping Agency Prohibited List, category S2 (peptide hormones, growth factors, and mimetics), as a growth hormone secretagogue. The prohibition is enforceable because detection is validated — accredited laboratories identify ipamorelin in urine at 2-10 pg/mL using high-resolution mass spectrometry ^[7], among several methods covering it and its metabolites ^[9][10]. So while it is not an approved medicine, it is very much a regulated substance — just under sport's rules rather than the drug-approval system.

What the recent reviews conclude

Independent reviews published in 2026 align with the regulatory record. A structured narrative review of injectable peptides in sports medicine classified ipamorelin as investigational, with no reproducible human evidence, recommending its use be confined to rigorous research protocols ^[16]. A review of approved and unapproved peptide therapies for musculoskeletal injury described it as investigational with preclinical signals but an absence of rigorous human trials and potential for serious harm ^[17]. The consistent message: ipamorelin is an unapproved, investigational compound — and the literature treats it as one.